BioCatalystWatch
KRYSWorkspace / KRYS / OverviewCompany library
Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

Krystal Biotech, Inc. (KRYS)

Website

Price
Market cap
Next catalystExpected 2026KB105 · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

KB801

NGF

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

KB707

IL-12 × IL-2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KB408

Neutrophil elastase (NE) × SERPINA1 transgene

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

KB407

CFTR transgene

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

KB111

ATP2C1 transgene

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

KB803

COL7A1 × Type VII collagen

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

KB707

IL-12 × IL-2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KB111

ATP2C1 transgene

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

KB407

CFTR transgene

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

KB408

Neutrophil elastase (NE) × SERPINA1 transgene

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

KB801

NGF

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

KB803

COL7A1 × Type VII collagen

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

IL-12 × IL-2

KB301

COL3A1 transgene

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Approved / commercial

COL7A1 transgene

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

KRYS PR & News

PR & News

KRYS SEC archive